Developing the next generation of oncolytic immunotherapy
Development of a potent, practical neo-antigen vaccines is currently a key objective of immuno-oncology. Oncolytic immunotherapy uniquely generates a potent, patient specific tumor neo-antigen vaccine directly in situ in the patient. Replimune aims to provide a highly potent ‘universal’ neo-antigen vaccine through it’s approach.
Tumor selective virus replication kills tumors. This releases the full array of neo-antigens in an inflamed tumor environment. Both innate and adaptive immune responses are triggered, including through TLR and STNG signaling. This provides systemic vaccination and systemic efficacy, and is highly synergistic with immune checkpoint blockade.